Collegium Pharmaceutical, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Collegium Pharmaceutical, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $481.00K, a 56.17% increase year-over-year.
- Collegium Pharmaceutical, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $394.00K, a 74.61% decline year-over-year.
- Collegium Pharmaceutical, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.44M, a 925.00% increase year-over-year.
- Collegium Pharmaceutical, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $308.00K, a 94.62% decline year-over-year.
- Collegium Pharmaceutical, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $4.28M, a 58.23% decline from fiscal 2024.
- Collegium Pharmaceutical, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $10.25M, a 18.57% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $8.64M, a 26.84% decline from fiscal 2022.
- Collegium Pharmaceutical, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $11.81M, a 0.49% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $481.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $394.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $4.28M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.44M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $308.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $1.55M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $10.25M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $140.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $5.73M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $4.21M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $8.64M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $302.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.25M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $3.85M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $11.81M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $142.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $1.54M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $3.26M 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $11.87M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $1.34M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $4.09M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $4.10M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $6.66M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $314.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.63M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $4.45M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $2.05M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $232.00K 10-Q · filed 2020-11-05 | $704.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $58.00K 10-Q · filed 2020-11-05 | $654.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $246.00K 10-Q · filed 2020-11-05 | $2.13M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $4.25M 10-K · filed 2021-02-25 |
| 2018-09-30 | $182.00K 10-Q · filed 2019-11-06 | $4.39M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $1.53M 10-Q · filed 2019-11-06 | $4.23M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $2.37M 10-Q · filed 2019-11-06 | $3.02M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $308.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $736.00K 10-K · filed 2020-02-27 |
| 2017-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $757.00K derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $321.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $772.00K derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $94.00K 10-Q · filed 2017-05-10 | $496.00K derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $329.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $443.00K 10-K · filed 2019-02-27 |
| 2016-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | |
| 2016-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | |
| 2016-03-31 | $41.00K 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $517.00K 10-K · filed 2018-03-07 | |
| 2014-12-31 | $72.00K 10-K · filed 2017-03-10 | |
| 2013-12-31 | $1.00K 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |